Nivolumab treatment of elderly Japanese patients with non-small cell lung cancer: subanalysis of a real-world retrospective observational study (CA209-9CR).

ESMO Open
Kyoichi OkishioYuichiro Ohe

Abstract

We conducted a subanalysis of data from the multicentre, retrospective observational Nivolumab Japan Real World (CA209-9CR) study to evaluate nivolumab effectiveness and safety in elderly patients (aged ≥75 years) with advanced/metastatic non-small cell lung cancer. Medical record data of patients initiating nivolumab treatment between April 2016 and December 2016 were collected using electronic data capture from 23 cancer hospitals in Japan between March 2017 and August 2018. Nivolumab treatment data were collected to investigate the treatment patterns by age group (<75 and ≥75 years), and the effectiveness and safety of nivolumab treatment. Of the 901 patients evaluated, 178 (19.8%) were aged ≥75 years. Overall, patients received a median of five nivolumab treatments regardless of age group. Comparable progression-free survival was observed, with a median of 2.1 months in patients aged <75 years and 2.1 months in patients aged ≥75 years (p=0.5441). No significant differences were found in duration of response, overall response rate or disease control rate between the two age groups. Median overall survival in patients aged <75 and ≥75 years was 14.7 months and 12.3 months, respectively. Grade ≥3 adverse events (AEs) occurred ...Continue Reading

References

Aug 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M K FergusonH M Golomb
Oct 13, 2004·The Oncologist·Paris D MakrantonakisPeter G Harper
Jan 6, 2006·The Cancer Journal·Rishi SawhneyArash Naeim
Mar 5, 2008·Mayo Clinic Proceedings·Taimur SherAlex A Adjei
Jul 22, 2010·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Eckart LaackCarsten Bokemeyer
Oct 21, 2010·The British Journal of Surgery·M KandaA Nakao
May 29, 2012·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Ramzi G SalloumJennifer Elston Lafata
Nov 2, 2013·Oncology Letters·Faruk TasSenem Karabulut
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Jul 15, 2016·Translational Lung Cancer Research·Cecilia Zappa, Shaker A Mousa
Jan 11, 2017·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Shlomit Strulov Shachar, Grant R Williams
Oct 13, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leora HornWilfried E E Eberhardt
Dec 20, 2017·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Elizabeth DudnikUNKNOWN Israel Lung Cancer Group
Mar 14, 2018·Journal of Geriatric Oncology·Renaud SabatierFrédérique Rousseau
Jul 18, 2018·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Francesco GrossiFilippo de Marinis
Oct 5, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D PlanchardUNKNOWN ESMO Guidelines Committee
May 3, 2019·International Journal of Clinical Oncology·Hiroaki AkamatsuNobuyuki Yamamoto
Nov 2, 2019·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Francesco GrossiEnrico Cortesi
Dec 16, 2019·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Ryo MoritaYuichiro Ohe
Oct 1, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D PlanchardUNKNOWN ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Clinical Trials Mentioned

NCT03273790

Software Mentioned

SAS

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Francesco GrossiFilippo De Marinis
Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Matteo Giaj LevraChristos Chouaïd
© 2021 Meta ULC. All rights reserved